European Neuropsychopharmacology

publication venue for

F5. GENE-ENVIRONMENTAL MODIFIERS USING POLYGENIC RISK AND STRUCTURAL EQUATION MODELLING IN LATE-LIFE DEPRESSION 2023
CASE-CONTROL ANALYSES OF MITOCHONDRIAL DNA IN ACCELEROMETRY-DERIVED SLEEP MEASURES IN DEPRESSED UK BIOBANK SUBJECTS 2022
EFFECTS OF CYP2C19, CYP2D6, AND ABCB1 GENE VARIANTS ON ESCITALOPRAM AND ARIPIPRAZOLE TREATMENT-RELATED SEXUAL SIDE EFFECTS: RESULTS FROM THE CAN-BIND-1 STUDY 2022
P.0092 The efficacy of smartphone-based interventions in bipolar disorder: systematic-review and meta-analyses. A position paper from the ISBD Big Data Task-Force 2021
P.0266 The mental health response to the first wave of covid-19 in an international sample 2021
TH42. APPLICATION OF REFERENCE-BASED CELL TYPE ESTIMATION IN PLACENTAL TISSUE AND COMPARISON WITH A REFERENCE-FREE APPROACH FOR DNA METHYLATION STUDIES 2021
P.250 Prediction of bipolar disorder four years before onset in a 22-year population-based birth cohort using advanced machine learning techniques 2020
P.492 Selective sound sensitivity (misophonia): characteristics of an online sample 2019
M31 IMPACT OF CYP2C19 AND CYP2D6 GENE VARIANTS ON PLASMA LEVELS AND TREATMENT RESPONSE IN PATIENTS RECEIVING ESCITALOPRAM AND ARIPIPRAZOLE FOR MAJOR DEPRESSION: RESULTS FROM THE CAN-BIND-1 COHORT 2019
E.01.01 Pharmacological treatment of resistant OCD 2019
GENETICS OF THE RESEARCH DOMAIN CRITERIA (RDoC): GENOME-WIDE ASSOCIATION STUDY OF DELAY DISCOUNTING 2019
GENOME-WIDE ASSOCIATION STUDY OF ALCOHOL USE DISORDER IDENTIFICATION TEST (AUDIT) SCORES IN AN UNSELECTED COHORT OF 20,328 RESEARCH PARTICIPANTS OF EUROPEAN ANCESTRY: RS41973904 AND BEYOND 2019
GWAS-BASED MACHINE LEARNING APPROACH TO PREDICT DULOXETINE RESPONSE AND REMISSION IN MAJOR DEPRESSIVE DISORDER 2019
Lisdexamfetamine dimesylate in adult ADHD with anxiety disorder and depression comorbidity: A 17-week cross-over study 2019
EXPLORING SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF OLDER ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER: A REPORT FROM THE INTERNATIONAL COLLEGE OF OBSESSIVE-COMPULSIVE DISORDERS (ICOCS) 2018
HOARDING IN USERS OF ONLINE CLASSIFIED ADVERTSEMENTS 2018
INTERNET ADDICTION OR PSYCHOPATHOLOGY IN DISGUISE? RESULTS FROM A SURVEY OF COLLEGE-AGED INTERNET USERS 2018
Clinical correlates of early-onset bipolar I disorder 2017
DIFFERENTIAL EXPRESSION OF TRANSCRIPTION FACTORS IN THE PREFRONTAL CORTEX OF INDIVIDUALS WITH BIPOLAR DISORDER 2017
GENOME-WIDE ASSOCIATION STUDY IN DULOXETINE AND PLACEBO RESPONSE 2017
GENOME-WIDE DE NOVO MUTATION LANDSCAPE IN AUTISM SPECTRUM DISORDER 2017
GWAS-BASED MACHINE LEARNING APPROACH TO PREDICT DULOXETINE RESPONSE IN MAJOR DEPRESSIVE DISORDER 2017
Pokémon Go: is it a potential tool for mental health? 2017
Predicting functional impairment in bipolar disorder: a pilot study with a machine learning approach 2017
Prevalence of anxiety and depressive symptoms in a Canadian medical cannabis use cohort 2017
THINKING AND DOING: THE EFFECTS OF DOPAMINE AND OXYTOCIN GENES AND EXECUTIVE FUNCTION ON MOTHERING BEHAVIOURS 2017
CHILDHOOD, ADOLESCENT AND ADULT AGE AT ONSET AND RELATED CLINICAL CORRELATES IN OBSESSIVE-COMPULSIVE DISORDER: A REPORT FROM THE INTERNATIONAL COLLEGE OF OBSESSIVE-COMPULSIVE DISORDERS (ICOCS) 2017
NEUROIMAGING OF SUBCORTICAL BRAIN VOLUME ALTERATIONS IN PEADIATRIC AND ADULT OBSESSIVE-COMPULSIVE DISORDER: Preliminary findings from the ENIGMA Obsessive-Compulsive Disorder working group 2017
Hoarding in users of online classified advertisements 2016
Improved resilience against depressed mood in early postpartum after dietary supplement administration 2016
Internet addiction or psychopathology in disguise? Results from a survey of college-aged internet users 2016
Prediction of early-onset eating disorders and obesity: the role of neuropsychological performance at age 4 2016
P.1.c.015 Cognitive development in 4-to 6-year old children: does the Cambridge neuropsychological test automated battery provide a reliable assessment? 2015
P.2.b.017 Structural brain alterations in major depression: findings from the ENIGMA Major Depressive Disorder Working Group 2015
P.2.c.008 Cell therapy as a strategy for the treatment of bipolar disorder: preliminary results of a study using an animal model of mania 2015
P.2.d.015 Short telomeres in subjects with remitted bipolar disorder 2015
P.2.h.003 Reduction in depressed mood after dietary supplementation during postpartum blues 2015
P.6.e.002 Problematic internet use in the general population: results from an internet-based survey 2015
S.20.04 Gut-brain communication: how the microbiome influences anxiety and depression 2015
P.1.i.034 The impact of 5-HTTLPR and BDNF Val66Met on heterogeneity of intrinsic connectivity of amygdala in major depressive disorder 2014
P.2.c.004 The receptor P2X7 participates in the amphetamine-induced increase of a proinflammatory environment in an animal model of mania 2014
P.2.c.005 Use of mesenchymal stem cells as a novel treatment for bipolar disorder: preliminary results of an in vitro study 2014
P.2.c.009 Epigenetically-induced modulation of the stress axis associated with the progression of bipolar disorder 2014
P.2.d.033 Staging bipolar disorder: biological, clinical and functional correlates 2014
P.2.d.054 A pilot, open-label, 8-week study evaluating the efficacy of adjunctive minocycline for the treatment of bipolar I/II depression 2014
P.4.a.007 Internet use for social communication in adolescents with social anxiety disorder 2014
P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review 2014
Evaluation of peripheral biomarkers in bipolar and unipolar depression 2013
P.1.g.067 Tianeptine has neuroprotective effects in a differentiated SH-SY5Y human neuroblastoma cell line 2013
P.1.g.078 Approaches to create dietary supplements to prevent postpartum depression 2013
P.2.d.009 The predictive role of Val66Met polymorphism on levels of BDNF along treatment of medication-free patients with bipolar disorder 2013
P.2.d.046 C-reactive protein is elevated in bipolar disorder 2013
P.4.e.007 Perceptions of obsessive compulsive disorder and the impact on treatment outcomes 2013
P.4.e.008 The use of technology-based communication and the impact on the social functioning of individuals with and without social phobia 2013
P.2.e.027 Interleukin-6 as a biomarker of the model of staging in bipolar disorder 2012
P.4.a.010 Adult attention deficit hyperactivity disorder and anxiety disorder comorbidity: prevalence in a clinical sample 2012
P.4.e.007 Internet screening for anxiety disorders and effects on treatment-seeking three months later 2012
P.4.f.003 Recent life stress in pregnant immigrant women and its association with HPA axis activity 2012
S.06.04 Staging and biomarkers in bipolar disorders 2012
Brain-derived neurotrophic factor as a biomarker of clinical response in bipolar disorder: 16-week follow-up study 2012
E.01.01 Overview 2011
P.2.e.001 Methylene blue for residual symptoms and for cognitive dysfunction in bipolar disorder: results of a double-blind trial 2011
P.4.b.005 Panic attacks and generalised anxiety disorder 2011
P.4.b.019 Panic attacks associated with generalised anxiety disorder 2010
S.22.02 Alostatic load and oxidative stress in bipolar disorder 2010
P.1.i.02l Neuroendocrine and psychological factors in chronic fatigue syndrome 2009
P.2.a.049 Functional outcome after 12 months of deep brain stimulation for treatment resistant major depressive disorder 2009
P.4.a.006 Internet-based screening of anxiety disorders 2009
P.4.f.001 The impact of changing diagnostic criteria in posttraumatic stress disorder (PTSD) 2009
P.4.e.006 Perinatal Obsessive-Compulsive Scale (POCS): preliminary data 2008
P.4.f.003 Effect of stress on brain activation patterns in women with postpartum obsessive-compulsive and depressive disorders 2008
P.8.a.034 The composite international diagnostic interview-for women (CIDI-VENUS): a pilot study 2008
P.8.b.002 Early maternal experience, maternal sensitivity, infant emotion regulation and HPA function 2008
S.06.03 Phenotyping OCD: new insights from animal behaviour 2008
S.15.03 Early experiences affect brain and behaviour: a comparison of rat and human mothers 2008
S.15.05 The risk:benefit ratio of using antidepressants during pregnancy 2008
P.4.a.008 A randomized placebo controlled trial of olanzapine in trichotillomania 2006
S.15.02 Dopamine model of OCD in rats 2006
A pilot study of topiramate augmentation in treatment resistant obsessive-compulsive disorder 2005
Tiagabine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study 2005
P.1.035 An open study of instant dose citalopram inpremenstrual dysphoric disorder 2004
P.3.008 Treatment of trichotillomania with atypicalantipsychotics: A case series 2004
P.1.190 Prevalence and management of depression with painful physical symptoms in a Canadian claims database 2003
P.3.048 Generalized anxiety disorder (GAD): Gender differences in clinical presentation and response to sertraline 2003
Cardiac conduction in females and males under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs 2002
Mood disorders and sexual dimorphism in neurotransmitter systems 2002
Predictors of remission in patients treated with sertraline for moderate to severe generalized social phobia 2002
Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report. 78:71-80. 2024
F43. EFFECTS OF CANDIDATE GENES AND POLYGENIC RISK ON THE DEVELOPMENT OF DEPRESSION IN A PEER VICTIMIZED POPULATION. 75:S244-S244. 2023
Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. 60:91-99. 2022
P.0415 Meta-analysis of cognitive performance in older adults with bipolar disorders. 53:S301-S302. 2021
P.0805 Impact of peritraumatic dissociation in hospitalized patients with COVID-19 pneumonia: a longitudinal study. 53:S589-S589. 2021
Impact of peritraumatic dissociation in hospitalized patients with COVID-19 pneumonia: A longitudinal study. 140:53-59. 2021
Early intervention for obsessive compulsive disorder: An expert consensus statement. 29:549-565. 2019
Manifesto for a European research network into Problematic Usage of the Internet. 28:1232-1246. 2018
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. 28:970-979. 2018
Sense of coherence as a coping mechanism for women with anxiety living in deprivation. 27:S988-S988. 2017
Epigenetic induction of melatonin MT 1 receptors by valproate: Neurotherapeutic implications. 27:828-832. 2017
Polygenic risk score and heritability estimates reveals a genetic relationship between ASD and OCD. 27:657-666. 2017
Generalized anxiety disorder and excess cancer deaths: findings from a large, longitudinal study. 26:S598-S598. 2016
New treatment models for compulsive disorders. 26:877-884. 2016
The cost and impact of compulsivity: A research perspective. 26:800-809. 2016
Association of ventral striatum monoamine oxidase-A binding and functional connectivity in antisocial personality disorder with high impulsivity: A positron emission tomography and functional magnetic resonance imaging study. 26:777-786. 2016
Individual- and area-level risk factors of generalised anxiety disorder in a British community cohort: findings from the EPIC-Norfolk study. 25:S556-S556. 2015
No effect of oral l-tryptophan or alpha-lactalbumin on total tryptophan levels in breast milk. 25:779-787. 2015
Verbal episodic memory along the course of schizophrenia and bipolar disorder: A new perspective. 25:169-175. 2015
The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). 23:865-871. 2013
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. 23:253-262. 2013
Illness duration and total brain gray matter in bipolar disorder: Evidence for neurodegeneration?. 18:717-722. 2008
Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. 12:269-272. 2002
Predictors of sertraline response in the treatment of generalized social phobia. 11:S304-S304. 2001
24-Week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment. 10:336-336. 2000
A placebo-controlled study of sertraline in generalized social phobia. 10:335-335. 2000
Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. 10:389-395. 2000
Nefazodone in social phobia: A pilot study. 8:S266-S266. 1998
Utility-based measures of health-related quality of life in depression. 6:128-128. 1996
The role of serotonin re-uptake inhibitors in forensic psychiatry. 1:364-365. 1991

European Neuropsychopharmacology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)